Episeras is a Bluetooth-enabled earpiece with a custom-designed, 3D-printed brain activity sensor which monitors for ...

The Episeras (formerly mjn-SERAS) device, developed by German specialty drugmaker Neuraxpharm and Spanish digital health ...

To find out, pharmaphorum chatted with Jack Kreindler (WellFounded) after his onstage session at Frontiers Health 2025.

A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for hereditary haemorrhagic telangiectasia (HHT), the second most common inherited ...

UK researchers have developed a platform that can test whether commercial AI algorithms developed for NHS applications are ...

YourCoach Health’s Eugene and Marina Borukhovich spoke with pharmaphorum after their Frontiers Health session to get to the ...

The FDA has started a priority review of BeOne Medicines' BCL2 inhibitor sonrotoclax in relapsed or refractory mantle cell ...

The attraction for Alkermes and Lundbeck in Avadel is Lumryz, an extended-release formulation of the well-established ...

Veeva’s latest report, The State of Data, Analytics, and AI in Commercial Biopharma, revealed a critical industry paradox: ...

The Autumn Budget, with its £26 billion tax rise by 2029-30, will “drive an exodus of wealth from Britain,” warned Nigel ...

Digital health and digital therapeutics have been around for a long time now. But when will we really start to realise the ...

Novo Nordisk is filing its supplemental new drug application (sNDA) for Wegovy 7.2 mg on the back of the phase 3b STEP UP ...